[go: up one dir, main page]

AR038947A1 - Suspension oral de sabor agradable y metodo - Google Patents

Suspension oral de sabor agradable y metodo

Info

Publication number
AR038947A1
AR038947A1 ARP030100851A ARP030100851A AR038947A1 AR 038947 A1 AR038947 A1 AR 038947A1 AR P030100851 A ARP030100851 A AR P030100851A AR P030100851 A ARP030100851 A AR P030100851A AR 038947 A1 AR038947 A1 AR 038947A1
Authority
AR
Argentina
Prior art keywords
drug
bitter taste
water
taste
dry powder
Prior art date
Application number
ARP030100851A
Other languages
English (en)
Inventor
Ismat Ullah
Gary J Wiley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR038947A1 publication Critical patent/AR038947A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulación de fármaco en forma de un polvo seco el cual cuando se mezcla con agua, forma una suspensión oral con sabor agradable, substancialmente libre de un sabor amargo, el polvo seco se forma de un fármaco preferiblemente des-quinolona que en solución tiene un sabor amargo, y un agente modificador del pH que es preferiblemente un material alcalino tal como la L-arginina, en donde al mezclar el polvo seco en agua se provoca que el fármaco tenga la solubilidad reducida o se precipite in situ para formar una suspensión oral de sabor agradable esencialmente libre de sabor amargo. También se proporciona una suspensión oral, métodos para la elaboración de la misma y un método para ocultar el sabor amargo de los fármacos que emplean uno o más agentes modificadores del pH. Reivindicación 1: Una composición farmacéutica en forma de un polvo seco que comprende partículas de un fármaco fácilmente soluble en agua, el cual cuando se solubiliza tiene un sabor amargo, y las partículas se tratan de manera que con al adición de agua a ellas, las partículas se hacen menos solubles o forman un precipitado in situ suspendido en el agua y está esencialmente libre de un sabor amargo, en donde el fármaco se hace libre del sabor amargo sin el uso o necesidad de un polímero o recubrimiento en cera o microencapsulación. Reivindicación 9: La composición farmacéutica como se define en la reivindicación 8, en donde el fármaco es un fármaco ácido que forma un precipitado con un agente alcalino modificador del pH o el fármaco es un fármaco básico que forma un precipitado con un agente modificador del pH ácido. Reivindicación 10: La composición farmacéutica como se define en la reivindicación 9, en donde el fármaco ácido es desquinolona, norfloxacino, ciprofloxacino u ofloxacino, y el fármaco básico es monohidratado de cloxacilin de sodio, monohidrato de dicloxicilin de sodio o ifetroban de sodio.
ARP030100851A 2002-03-12 2003-03-12 Suspension oral de sabor agradable y metodo AR038947A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36370402P 2002-03-12 2002-03-12

Publications (1)

Publication Number Publication Date
AR038947A1 true AR038947A1 (es) 2005-02-02

Family

ID=28041802

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100851A AR038947A1 (es) 2002-03-12 2003-03-12 Suspension oral de sabor agradable y metodo

Country Status (16)

Country Link
US (1) US7175856B2 (es)
EP (1) EP1482789A4 (es)
JP (1) JP4619658B2 (es)
CN (1) CN100337630C (es)
AR (1) AR038947A1 (es)
AU (1) AU2003220058B2 (es)
BR (1) BR0308343A (es)
CA (1) CA2478411C (es)
MX (1) MXPA04008720A (es)
NO (1) NO20043986L (es)
NZ (1) NZ534746A (es)
PE (1) PE20030885A1 (es)
PL (1) PL212421B1 (es)
TW (1) TW200304832A (es)
WO (1) WO2003077842A2 (es)
ZA (1) ZA200406585B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005023193D1 (de) * 2004-10-15 2010-10-07 Suedzucker Ag Verbessertes trommelcoating-verfahren
US8653145B2 (en) * 2005-09-22 2014-02-18 Eaton Scientific Systems, Ltd. Method for alleviating climacteric symptoms
CN102964296B (zh) 2007-03-28 2015-03-25 阿普泰克斯科技公司 去铁酮的氟化衍生物
US20100210604A1 (en) 2007-06-13 2010-08-19 Meythaler Jay M Zwitterion solution for low-volume therapeutic delivery
US20110021469A1 (en) * 2007-06-13 2011-01-27 Meythaler Jay M baclofen solution for low-volume therapeutic delivery
JP5009707B2 (ja) * 2007-07-10 2012-08-22 東和薬品株式会社 不快な味がマスキングされたキノロン系抗菌剤の経口投与用液剤
US7884227B2 (en) * 2007-10-26 2011-02-08 Navinta Llc Felbamate with improved bulk density
GB2470494B (en) * 2008-01-17 2012-08-08 Univ Holy Ghost Duquesne Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS
CN102014904B (zh) * 2008-04-25 2013-02-06 阿普泰克斯科技公司 具有适口味道的去铁酮液体配制品
ES2351643B1 (es) * 2009-07-27 2011-09-15 Laboratorio Jaer,S.A. Utilización de xilitol o sus derivados para el enmascaramiento gustativo de quimioterápicos del grupo del ácido quinolon-o-naftiridoncarboxílico administrados en alimentos destinados a ganado porcino.
EP2343089A4 (en) 2008-09-23 2013-05-01 Jaer S A Lab USE OF XYLITOL OR DERIVATIVES THEREOF FOR MASKING THE TASTE OF CHEMOTHERAPEUTIC MEDICAMENTS OF THE CHINOLO-N-NAPHTHYRIDONE-CARBOXYLIC ACID GROUP FOR PIG DICULTINATION
ES2335334B1 (es) * 2008-09-23 2011-02-09 Laboratorio Jaer, S.A. Utilizacion del xilitol para el enmascaramiento gustativo de amargantes en alimentos para animales.
WO2011000104A1 (en) 2009-07-03 2011-01-06 Apotex Technologies Inc. Fluorinated derivatives of 3-hydroxypyridin-4-ones
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
US20110236494A1 (en) * 2010-03-04 2011-09-29 Ranbaxy Laboratories Limited Ciprofloxacin oral suspension
GB201006218D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
CN102397546A (zh) * 2010-09-10 2012-04-04 广州自远生物科技有限公司 一种用于嗅觉或味觉敏感型动物的药物给药方法
CN102397552B (zh) * 2010-09-10 2016-06-08 广州自远生物科技有限公司 一种含喹诺酮类的药物复合制剂及其制备方法和应用
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
LT3524595T (lt) 2014-08-28 2022-09-26 Eisai R&D Management Co., Ltd. Aukšto grynumo chinolino darinys ir jo gamybos būdas
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
US11648202B2 (en) * 2017-10-13 2023-05-16 Research Triangle Institute Hydroxychloroquine sulfate formulations and methods for preparation and use thereof
CN110151704A (zh) * 2019-07-05 2019-08-23 华裕(无锡)制药有限公司 阿奇霉素干混悬剂的制备方法
WO2025043236A1 (en) * 2023-08-24 2025-02-27 Joseph Fuisz Edible oral films, compositions, method of manufacture and packaging systems

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8103843L (sv) 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
CA1239349A (en) * 1983-10-10 1988-07-19 Eberhard F. Gottwald Pharmaceutical composition containing cimetidine
JPS61180771A (ja) * 1985-01-05 1986-08-13 バイエル・アクチエンゲゼルシヤフト 安定な抗バクテリア剤水溶液
GB8623557D0 (en) * 1986-10-01 1986-11-05 Boots Co Plc Therapeutic agents
NL193682C (nl) 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
DE3719764A1 (de) * 1987-06-13 1988-12-22 Bayer Ag Ionenaustauscherharze beladen mit chinoloncarbonsaeurederivaten, ihre herstellung und verwendung
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
DE3831514A1 (de) * 1988-09-16 1990-03-22 Bayer Ag Ph-neutrale waessrige loesungen von chinoloncarbonsaeuren
US4975465A (en) * 1989-03-28 1990-12-04 American Home Products Corporation Orally administrable ibuprofen compositions
US5262179A (en) * 1989-09-13 1993-11-16 Nicholas Kiwi Pty Ltd. Non-effervescent ibuprofen compositions
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
IT1246383B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
JP3184239B2 (ja) * 1991-04-25 2001-07-09 京都薬品工業株式会社 矯味経口用医薬組成物
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
JPH05309314A (ja) 1992-05-07 1993-11-22 Sumitomo Pharmaceut Co Ltd コーティング方法
ZA945944B (en) 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
NZ290946A (en) * 1994-08-12 1997-12-19 Toyama Chemical Co Ltd Quinolone- or naphthyridone-carboxylic acid derivatives
AU689663B2 (en) * 1994-10-14 1998-04-02 Janssen Pharmaceutica N.V. Sabeluzole oral suspensions
GB9421837D0 (en) * 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms
ZA961018B (en) * 1995-02-08 1997-08-08 Yamanouchi Europ Bv Oral dosage-forms containing a beta-lactam antibiotic.
US5972379A (en) 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
CN1100053C (zh) * 1996-02-09 2003-01-29 富山化学工业株式会社 喹诺酮羧酸衍生物或它们的盐类
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
JP3424038B2 (ja) * 1996-06-17 2003-07-07 株式会社日本点眼薬研究所 合成抗菌剤水性組成物
AP1409A (en) * 1999-05-27 2005-06-13 Pfizer Prod Inc Ziprasidone suspension.
US6239141B1 (en) * 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions

Also Published As

Publication number Publication date
PE20030885A1 (es) 2003-10-23
TW200304832A (en) 2003-10-16
US7175856B2 (en) 2007-02-13
ZA200406585B (en) 2005-11-30
CN1642415A (zh) 2005-07-20
CN100337630C (zh) 2007-09-19
NO20043986L (no) 2004-09-23
BR0308343A (pt) 2006-06-06
CA2478411C (en) 2010-09-28
WO2003077842A3 (en) 2004-03-25
MXPA04008720A (es) 2004-12-06
US20030187019A1 (en) 2003-10-02
WO2003077842A2 (en) 2003-09-25
NZ534746A (en) 2006-06-30
EP1482789A4 (en) 2010-12-29
EP1482789A2 (en) 2004-12-08
JP4619658B2 (ja) 2011-01-26
CA2478411A1 (en) 2003-09-25
JP2006504620A (ja) 2006-02-09
PL212421B1 (pl) 2012-09-28
AU2003220058B2 (en) 2008-05-01
AU2003220058A1 (en) 2003-09-29
PL373570A1 (en) 2005-09-05

Similar Documents

Publication Publication Date Title
AR038947A1 (es) Suspension oral de sabor agradable y metodo
WO2005065646A3 (en) Novel drug compositions and dosage forms
IL161290A0 (en) Stable composition comprising particles in a frozen aqueous matrix
TR200500745T2 (tr) Damar gelişimi inhibitörleri olarak kuinazolin türevleri.
ECSP044974A (es) Formulación de suspensión oral estabilizada
JO3404B1 (ar) تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
AR111572A2 (es) Formas farmacéuticas que contienen vardenafilo
UY27273A1 (es) Solución oral de arilpiprazol
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
DK1587514T3 (da) Hurtigvirkende farmaceutisk præparat
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
WO2005065648A3 (en) Novel drug compositions and dosage forms of topiramate
NI200600146A (es) Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso
FR2846327B1 (fr) Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
AR043536A1 (es) Composicion farmaceutica que comprende acido 5-metil-2-(2´-cloro-6´-fluoroanilino)fenilacetico
JP2002537246A5 (es)
EP1634585A4 (en) MEDICINAL PRODUCTS CONTAINING DELAYED MICROTEIL, PROCESS FOR ITS PREPARATION AND MICROPARTICLE CONTAINING PREPARATION
DE60007074D1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
MA27850A1 (fr) Preparations pharmaceutiques contenant de l'amoxicilline et du clavulanate
ATE390126T1 (de) Zubereitungen mit verzögerter freigabe enthaltend zink, und herstellung derselben
ATE425741T1 (de) Arzneizubereitung und deren anwendung zur behandlung von erkrankungen des inneren ohres

Legal Events

Date Code Title Description
FA Abandonment or withdrawal